EUVIMEDEUVIMED entdecken
Übersichtsarbeit

High-throughput screening for ageing and age-related disease drug discovery: Advances and challenges

Xingkun Ji, Yan Pan, Jiajun Lei, Lisha Liang, Changquan Wang, Xinyi Zeng, Danyang Yu, Fangyi Chen, Jiongming Lu, Jian-Kang Zhu, Alessandro Cellerino, Judith Bossen und 2 weitere

Ageing Research Reviews · 2026

DOI: 10.1016/j.arr.2026.103124 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Ageing Research Reviews, 2026. Verfasst von Xingkun Ji und 13 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Advanced Biotechnology, Institute of Homeostatic Medicine, and School of Medicine, Southern University of Science and Technology, Shenzh…. Hauptthemen laut MEDLINE: Aging, High-Throughput Screening Assays, Drug Discovery. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 189 Literaturangaben. Gefördert von: Shenzhen-Hong Kong Institute of Brain Science, Science and Technology Planning Project of Guangdong Province, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ageing is the primary risk factor for many chronic, degenerative, and life-threatening disorders, yet the translational pipeline for geroprotective interventions remains comparatively sparse. Short‑lived, experimentally tractable models with conserved ageing pathways, particularly Caenorhabditis elegans, Drosophila melanogaster, and the African turquoise killifish (Nothobranchius furzeri), have expanded discovery beyond traditionally mammalian-centric pipelines. By leveraging advances in automation, high-content imaging, and artificial intelligence (AI), these models have shifted the field from low-throughput, reductionist assays to scalable, mechanistically informed in vivo phenotypic discovery. Here, we review recent advances in middle- to high-throughput screening (HTS) technologies across these models, review key phenotypic and molecular biomarkers, such as motility, cognition and memory, intestinal integrity, mitochondrial function, and immune response, and discuss their strengths and limitations. We further evaluate the expanding role of AI from in silico screening, automated and high-content phenotyping, to integrative multi-layer mechanistic inference. Key challenges, including data standardisation, reproducibility across laboratories, limited cross‑species pharmacokinetic comparability, AI model interpretability, and the translational gap between invertebrate hits and vertebrate or mammalian efficacy, are also discussed. By highlighting recent developments in in vivo disease models, HTS methodologies, and AI integration, this review provides a comprehensive resource for developing effective models and screening strategies to accelerate therapeutics for ageing and age-related diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AgingHigh-Throughput Screening AssaysDrug DiscoveryAnimalsHumansArtificial Intelligence

Stichwörter der Autor:innen

Age-related diseasesAgeingArtificial intelligenceHigh-throughput screeningModel organisms

Autor:innen und Institutionen

  • Institute of Advanced Biotechnology, Institute of Homeostatic Medicine, and School of Medicine, Southern University of Science and Technology, Shenzhen, China.
  • Laboratory of Aging Research, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
  • Department of Biomedical Engineering, Southern University of Science and Technology, Shenzhen, China; Changsha Normal University, Changsha, China.
  • Sirio Institute on Ageing (SIA), Sirio Life Technology Co., Ltd, Shanghai, China.
  • Department of Biomedical Engineering, Southern University of Science and Technology, Shenzhen, China.
  • Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, China.

Förderung

  • Shenzhen-Hong Kong Institute of Brain Science
  • Science and Technology Planning Project of Guangdong Province
  • National Natural Science Foundation of China
  • Shenzhen Science and Technology Innovation Program
  • Southern University of Science and Technology
  • National Key Research and Development Program of China
  • Max Planck Society

Zitieren

APA

Ji, X., Pan, Y., Lei, J., Liang, L., Wang, C., Zeng, X., Yu, D., Chen, F., Lu, J., Zhu, J. K., Cellerino, A., Bossen, J., Xian, B., & Lyu, Y. X. (2026). High-throughput screening for ageing and age-related disease drug discovery: Advances and challenges. Ageing Research Reviews. https://doi.org/10.1016/j.arr.2026.103124

Vancouver

Ji X, Pan Y, Lei J, Liang L, Wang C, Zeng X, et al. High-throughput screening for ageing and age-related disease drug discovery: Advances and challenges. Ageing Research Reviews. 2026. doi:10.1016/j.arr.2026.103124

BibTeX
@article{Ji2026,
  author = {Ji, Xingkun and Pan, Yan and Lei, Jiajun and Liang, Lisha and Wang, Changquan and Zeng, Xinyi and Yu, Danyang and Chen, Fangyi and Lu, Jiongming and Zhu, Jian-Kang and Cellerino, Alessandro and Bossen, Judith and Xian, Bo and Lyu, Yu-Xuan},
  title = {High-throughput screening for ageing and age-related disease drug discovery: Advances and challenges},
  journal = {Ageing Research Reviews},
  year = {2026},
  doi = {10.1016/j.arr.2026.103124}
}
Kostenlos starten →